...
首页> 外文期刊>Journal of nephrology. >High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.
【24h】

High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.

机译:高敏C反应蛋白可预测原发性经皮冠状动脉介入治疗后对比剂诱发的肾病。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Few studies have investigated hs-CRP as a risk factor for contrast-induced nephropathy (CIN). The aim of this study was to evaluate the predictive value of high-sensitivity C-reactive protein (hs-CRP) for risk of CIN in patients with acute ST-segment elevation myocardial infarction (STEMI) who were undergoing primary percutaneous coronary intervention (PCI).We prospectively observed 165 consenting patients with STEMI undergoing primary PCI. An increase in serum creatinine of more than 0.5 mg/dL from baseline within 48-72 hours of contrast media exposure was defined as CIN. Demographics, traditional risk factors, CIN incidence and other in-hospital clinical outcomes were compared among hs-CRP quartiles. Receiver operator characteristic curves were used to identify the optimal sensitivity for the observed range of hs-CRP. The predictive value of hs-CRP for the risk of CIN was assessed using multivariate logistic regression.CIN occurred in 17 patients (10%). Univariate analysis revealed CIN incidence was significantly associated with hs-CRP, with 2.4% for quartile Q1 (<6.00 mg/L), 2.3% for Q2 (6.00-13.90), 12.5% for Q3 (13.91-32.75) and 24.4% for Q4 (>32.75) (P-trend <0.001), as was in-hospital death (0% for Q1, 2.3% for Q2, 5% for Q3 and 12.2% for Q4; P-trend = 0.009). Receiver operator characteristic curve analysis showed that an hs-CRP of 16.10 mg/L was a fair discriminator for the early creatinine increase (C statistic 0.78). After adjusting for potential confounding predictors, hs-CRP >16.10 mg/L remained significantly associated with CIN (odds ratio = 6.51; 95% confidence interval, 1.26-33.61).An hs-CRP >16.10 was a significant and independent predictor of CIN after primary PCI in patients with STEMI.
机译:很少有研究将hs-CRP作为造影剂诱发的肾病(CIN)的危险因素。这项研究的目的是评估高敏C反应蛋白(hs-CRP)对接受原发性经皮冠状动脉介入治疗(PCI)的急性ST段抬高型心肌梗死(STEMI)患者的CIN风险的预测价值)。我们前瞻性观察了165例同意接受STEMI治疗的原发性PCI患者。在造影剂暴露后48-72小时内,血清肌酐比基线增加超过0.5 mg / dL被定义为CIN。在hs-CRP四分位数之间比较了人口统计学,传统危险因素,CIN发生率和其他医院内临床结局。接收者操作员特征曲线用于确定在hs-CRP观察范围内的最佳灵敏度。 hs-CRP对CIN风险的预测价值通过多因素Logistic回归进行评估.CIN发生在17例患者中(10%)。单因素分析显示CIN发生率与hs-CRP显着相关,四分位数Q1(<6.00 mg / L)为2.4%,Q2为2.3%(6.00-13.90),Q3为12.5%(13.91-32.75),Qs为24.4%第四季度(> 32.75)(P趋势<0.001),以及院内死亡(第一季度为0%,第二季度为2.3%,第三季度为5%,第四季度为12.2%; P趋势= 0.009)。接收者操作者特征曲线分析表明,hs-CRP为16.10 mg / L是早期肌酐升高的合理判别指标(C统计值为0.78)。校正潜在的混杂预测因素后,hs-CRP> 16.10 mg / L仍与CIN显着相关(优势比= 6.51; 95%置信区间为1.26-33.61)。hs-CRP> 16.10是CIN的重要独立指标。 STEMI患者接受原发性PCI后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号